Allurion Technologies (ALUR)
OTHER OTC:ALUR
Want to see ALUR full AI Analyst Report?
Top Page
Allurion Technologies
(OTC:ALUR)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.83
▲(4.25% Upside)
Action:Reiterated
Date:05/16/26
The score is primarily held down by weak financial performance (shrinking revenue, very large losses, heavy cash burn, and negative equity). Technicals provide only a modest near-term offset, while valuation remains unfavorable due to losses and no dividend. Corporate events are mixed, with FDA approval positive but outweighed by delisting/OTC transition and dilution/financing risk.
Positive Factors
FDA PMA Approval — U.S. Market Access
PMA approval is a structural milestone enabling direct U.S. commercialization and reimbursement discussions, materially expanding the company’s addressable market. This regulatory clearance supports durable demand growth potential and provider adoption versus relying solely on ex‑US markets.
Negative Factors
Multi‑year Revenue Decline
A persistent multi‑year revenue contraction indicates structural demand or commercialization execution issues. Recovering to scale will require sustained commercial investment and adoption in the U.S.; absent durable top‑line stabilization, profitability and cash runway remain at risk.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA PMA Approval — U.S. Market Access
PMA approval is a structural milestone enabling direct U.S. commercialization and reimbursement discussions, materially expanding the company’s addressable market. This regulatory clearance supports durable demand growth potential and provider adoption versus relying solely on ex‑US markets.
Read all positive factors
Allurion Technologies (ALUR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.45M
Dividend YieldN/A
Average Volume (3M)88.72K
Price to Earnings (P/E)―
Beta (1Y)2.64
Revenue Growth-55.49%
EPS Growth21.55%
CountryUS
Employees134
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding15,006,253
10 Day Avg. Volume45,410
30 Day Avg. Volume88,723
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-1.20
Price to Sales (P/S)6.09
P/FCF Ratio-3.21
Enterprise Value/Market Cap2.48
Enterprise Value/Revenue2.45
Enterprise Value/Gross Profit4.65
Enterprise Value/Ebitda-0.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Allurion Technologies Business Overview & Revenue Model
Company Description
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Bal...
How the Company Makes Money
Allurion primarily generates revenue from the commercialization of its weight-loss solution centered on the Allurion Balloon. Revenue is earned through the sale of the balloon and associated program components delivered to healthcare providers/cli...
Allurion Technologies Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.60M | 15.23M | 32.11M | 53.47M | 64.21M | 38.24M |
| Gross Profit | 6.64M | 9.57M | 21.50M | 41.50M | 50.73M | 29.19M |
| EBITDA | -38.94M | -27.70M | -22.17M | -69.03M | -32.28M | -8.01M |
| Net Income | -33.35M | -28.75M | -26.15M | -80.61M | -37.74M | -12.39M |
Balance Sheet | ||||||
| Total Assets | 13.99M | 15.77M | 32.81M | 71.71M | 51.37M | 39.35M |
| Cash, Cash Equivalents and Short-Term Investments | 5.06M | 5.41M | 15.38M | 38.04M | 7.68M | 25.84M |
| Total Debt | 29.45M | 29.04M | 37.92M | 41.86M | 59.53M | 26.14M |
| Total Liabilities | 91.91M | 92.96M | 110.79M | 142.20M | 83.68M | 73.64M |
| Stockholders Equity | -77.91M | -77.19M | -77.98M | -70.49M | -32.31M | -34.28M |
Cash Flow | ||||||
| Free Cash Flow | -22.70M | -28.95M | -42.91M | -65.59M | -48.53M | -15.24M |
| Operating Cash Flow | -22.70M | -28.95M | -42.30M | -63.98M | -46.98M | -14.33M |
| Investing Cash Flow | 0.00 | 0.00 | -611.00K | -1.61M | -1.55M | -912.00K |
| Financing Cash Flow | 7.34M | 18.97M | 20.21M | 95.99M | 30.54M | 28.95M |
Allurion Technologies Technical Analysis
Negative
0.80
Price Trends
0.76
Positive
0.99
Negative
1.44
Negative
Market Momentum
0.02
Negative
50.18
Neutral
23.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALUR, the sentiment is Negative. The current price of 0.8 is above the 20-day moving average (MA) of 0.78, above the 50-day MA of 0.76, and below the 200-day MA of 1.44, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 50.18 is Neutral, neither overbought nor oversold. The STOCH value of 23.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALUR.
Allurion Technologies Risk Analysis
Allurion Technologies disclosed 88 risk factors in its most recent earnings report. Allurion Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Allurion Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $12.45M | -3.70 | 58.76% | ― | -55.49% | 21.55% | |
46 Neutral | $18.26M | -0.11 | -70.27% | ― | -9.46% | 18.03% | |
46 Neutral | $5.09M | ― | -279.58% | ― | 129.04% | 74.30% | |
46 Neutral | $7.32M | -0.43 | -57.19% | ― | ― | 27.91% | |
45 Neutral | $17.58M | -8.10 | -148.64% | ― | 7.73% | 55.39% | |
44 Neutral | $10.32M | -0.89 | -204.04% | ― | -59.95% | 56.67% |
* Healthcare Sector Average
ALUR
Allurion Technologies
0.80
-1.98
-71.22%
IRIX
Iridex
1.04
0.10
10.64%
SINT
Sintx Technologies
2.43
-0.23
-8.65%
CODX
Co-Diagnostics
9.11
1.64
21.95%
XAIR
Beyond Air
0.44
-3.36
-88.50%
NVNO
enVVeno Medical
11.25
-118.60
-91.34%
Allurion Technologies Corporate Events
Business Operations and StrategyDelistings and Listing Changes
Allurion Faces NYSE Delisting, Shifts Trading to OTC
Negative
Mar 12, 2026
On March 6, 2026, the New York Stock Exchange moved to delist Allurion Technologies’ common stock and warrants after the company fell below the required $15 million average global market capitalization over 30 consecutive trading days, promp...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Allurion Technologies Appeals NYSE Delisting, Plans Compliance Strategy
Negative
Mar 2, 2026
On March 2, 2026, Allurion Technologies announced that it had received a delisting notice from the New York Stock Exchange after failing to meet the exchange’s continued listing standards requiring at least $50 million in stockholders’...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Allurion Technologies Amends Warrants to Bolster Liquidity
Positive
Feb 25, 2026
On February 24, 2026, Allurion Technologies, Inc. entered into an inducement agreement with certain warrant holders to amend existing warrants issued in 2025 by cutting their exercise prices to $1.15 per share. In return, these investors agreed to...
Business Operations and StrategyProduct-Related Announcements
Allurion Wins FDA Approval for Gastric Balloon System
Positive
Feb 23, 2026
On February 23, 2026, Allurion Technologies announced that the U.S. Food and Drug Administration granted PMA approval for its Allurion Gastric Balloon System, featuring the swallowable Allurion Smart Capsule, for adults aged 22 to 65 with obesity ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.